Re: Amended and Restated Employment Terms Dear Jen:Millendo Therapeutics, Inc. • March 29th, 2021 • Pharmaceutical preparations
Millendo Therapeutics US, Inc. (the “Company”) desires to amend and restate the terms of your employment in connection with your appointment as Chief Financial Officer of the Company pursuant to the terms of this letter (the “Agreement”). Subject to your execution of this Agreement, effective as of February 1, 2021 (the “Effective Date”) this Agreement amends, restates and supersedes in its entirety your Employment Terms with Millendo Therapeutics US, Inc. effective January 1, 2019 (the “Prior Agreement”).
January 27, 2021 Confidential JULIA C. OWENSLetter Agreement • March 29th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
The purpose of this letter agreement (“Agreement”) is to confirm the terms of your separation of employment from Millendo Therapeutics US, Inc. (“Millendo” or “the Company”). Except for the obligations set forth in Section 2 which shall be solely the obligations of Millendo Therapeutics US, Inc., the term “Millendo” or the “Company” as otherwise used in this Agreement shall be deemed to include Millendo Therapeutics, Inc., and any and all of its divisions, franchisees, licensees, affiliates, parents, subsidiaries, and all related entities, and its and their directors, officers, employees, partners, members, representatives, trustees, agents, successors, predecessors, and assigns. The Severance Pay and Benefits described below are contingent on your agreement to and compliance with the provisions of this Agreement, as set forth below. This Agreement shall be effective on the eighth (8th) day after you sign and do not revoke it (the “Effective Date”).
